Migraine Natural & Non-Drug Adjuncts: The Evidence
What the evidence actually supports for riboflavin, magnesium and CoQ10 as migraine prophylaxis adjuncts in India, and where they fit alongside pharmacological therapy.
This is a clinical evidence reference for prescribers weighing where nutraceutical adjuncts genuinely fit in migraine management in India, alongside the pharmacological landscape of NSAIDs, triptans and newer CGRP-pathway drugs — not a home-remedy guide for patients to self-manage migraine.
What counts as migraine natural adjunct therapy in the clinical literature?
Migraine natural adjuncts in the peer-reviewed literature are limited to a short list: riboflavin, magnesium and coenzyme Q10, studied specifically as prophylactic add-ons rather than acute-attack treatments. No other commonly marketed "natural migraine" product has comparable controlled-trial support.
What does the actual evidence say about riboflavin for migraine?
Riboflavin (vitamin B2) has the strongest evidence base among migraine natural adjuncts, with a systematic review finding a majority of the studies reviewed demonstrating measurable efficacy in reducing migraine frequency. The proposed mechanism runs through riboflavin's role in mitochondrial oxidative metabolism, since migraine has a documented association with impaired cerebral energy metabolism in susceptible patients.
The effect size in trials is modest compared to first-line prophylactic drugs, and riboflavin's real clinical role is as a low-risk adjunct in patients seeking to reduce their pharmacological burden, not a replacement for a prophylactic agent in patients with frequent or disabling attacks.
Does magnesium supplementation actually reduce migraine frequency?
A substantial body of evidence documents magnesium deficiency in migraine patients specifically, which underpins the rationale for supplementation as prophylaxis rather than a general wellness intervention. Magnesium's proposed mechanism involves modulating neuronal excitability and cortical spreading depression, the electrophysiological process implicated in migraine aura.
Clinical trial evidence supports a preventive benefit at appropriate doses, though the literature notes meaningful variability in study quality and dosing protocols, meaning magnesium's real-world effect size is less firmly established than riboflavin's despite the strong biological rationale.
What about coenzyme Q10 specifically?
A double-blind, randomised, placebo-controlled trial found CoQ10 significantly reduced migraine attack frequency in adult patients over a three-month course, one of the better-controlled single-agent trials in this space. CoQ10 shares the mitochondrial-metabolism rationale with riboflavin, targeting the same underlying energy-production pathway implicated in migraine susceptibility.
A separate Class I trial testing riboflavin, magnesium and CoQ10 combined against placebo in 130 adult migraine patients adds evidence for a combined-nutraceutical approach specifically, rather than any single agent alone, which is how several of these adjuncts are now used together in practice.
Where do these adjuncts fit against India's actual migraine prescribing landscape?
Current Indian migraine prescribing centres on NSAIDs and fixed-dose combinations for acute attacks, with tricyclic antidepressants, propranolol and flunarizine as the dominant prophylactic agents, according to a recent review of migraine treatment profiles in India. Triptans remain superior to plain analgesics for pain freedom at two hours, and newer CGRP-pathway drugs including erenumab (monoclonal antibody prophylaxis) and lasmiditan (abortive therapy) are now prescribed in India as well.
Nutraceutical adjuncts occupy a genuinely useful niche in this landscape: patients intolerant of beta-blockers or TCAs, those wanting to minimise total pharmacological burden, or those already on an effective regimen looking to reduce attack frequency further. They are not positioned in the evidence base as a substitute for triptans in acute treatment or for standard prophylactic drugs in patients with frequent, disabling attacks.
Are there safety concerns or interactions with these adjuncts?
Riboflavin and CoQ10 both carry low toxicity profiles at studied doses and minimal known drug interaction risk, which is part of why they're used as adjuncts rather than avoided in polypharmacy patients. Magnesium supplementation, by contrast, carries genuine interaction and safety considerations: it can reduce absorption of oral bisphosphonates and certain antibiotics (tetracyclines, fluoroquinolones) if not spaced apart, and requires caution in patients with renal impairment given reduced magnesium clearance.
None of these adjuncts are risk-free simply because they are classified as supplements rather than prescription drugs, and a hospital pharmacy stocking them should apply the same interaction-screening discipline used for any other agent added to a patient's regimen.
What does this mean for a hospital's neurology and pharmacy stocking decisions?
A neurology OPD managing migraine at volume is prescribing across acute agents (NSAIDs, triptans), prophylactic drugs (propranolol, flunarizine, TCAs, increasingly CGRP-pathway drugs) and, for a meaningful subset of patients, evidence-supported nutraceutical adjuncts. A pharmacy that stocks only the acute-attack drugs and treats prophylaxis and adjuncts as the patient's own problem to source elsewhere loses the refill relationship on a chronic, recurring condition that generates repeat visits by definition.
Our piece on prescription leakage and hospital revenue loss covers what that recurring-prescription leakage costs a hospital over time, managed hospital pharmacy services covers the stocking model that keeps chronic-disease refills, including migraine prophylaxis, inside the hospital, and pharmacy inventory management covers keeping slower-moving prophylactic and adjunct stock from becoming dead stock.
Sources
- 1Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine — a meta-analysis — PMC, National Institutes of Health
- 2Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis — PubMed
- 3A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis — PMC, National Institutes of Health
- 4Prophylaxis of migraine headaches with riboflavin: A systematic review — Journal of Clinical Pharmacy and Therapeutics
- 5The Treatment Profile of Migraine in India: A Glimpse — Neurology India, Wolters Kluwer
This article is for informational purposes and is intended for clinicians and hospital administrators. It is not a substitute for professional medical advice, diagnosis or treatment, and contains no dosage instructions. Consult a qualified doctor for any individual patient's care.
FAQ
Frequently asked questions
Riboflavin, magnesium and CoQ10 have genuine trial evidence as prophylactic adjuncts, but none has evidence supporting them as a standalone replacement for pharmacological treatment in patients with frequent or disabling migraine. They are best evidenced as an addition to, not a substitute for, standard care.
Yes. Magnesium can reduce absorption of oral bisphosphonates and tetracycline or fluoroquinolone antibiotics if taken together, and requires dose caution in patients with reduced kidney function, since magnesium is cleared renally.
Riboflavin has the broadest base of supportive trial evidence among nutraceutical migraine adjuncts, with a majority of reviewed studies showing measurable frequency reduction, though effect sizes remain smaller than first-line prophylactic drugs.
Yes. Erenumab, a monoclonal antibody targeting the CGRP pathway, is used for migraine prophylaxis in India, and lasmiditan, a 5-HT1F receptor agonist, is used for acute abortive treatment, both representing a newer drug class beyond triptans and traditional prophylactics.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.